drugset

drugset / Trial / NCT01949324

A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel

NCT01949324 ↗

Phase 2 Completed 67 enrolled Neurotech Pharmaceuticals The Emmes Company, LLC · collab The Lowy Medical Research Institute Limited · collab

RandomizedParallel-groupSingle-blindTreatment

Summary

This study is a phase 2, randomized, multi-center, single-masked study to evaluate the efficacy and safety of the NT-501 implants in participants with Mactel.

Timeline

Start: 2014-04
Primary completion: 2017-04-14
Completion: 2017-05-22

Publications

Loo J, Cai CX, Choong J, Chew EY, Friedlander M, Jaffe GJ, Farsiu S. Deep learning-based classification and segmentation of retinal cavitations on optical coherence tomography images of macular telangiectasia type 2. Br J Ophthalmol. 2022 Mar;106(3):396-402. doi: 10.1136/bjophthalmol-2020-317131. Epub 2020 Nov 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ciliary neurotrophic factor	Cell therapy	—	—

Indications